Paolo Fundarò has over 20-year experience in capital markets, the last 15 years of which in the life science industry.
He received a degree in Business Management from Bocconi University in Milan, Italy. Earlier in his career, Mr. Fundarò worked for investment banks Salomon Smith Barney (now Citigroup) and Donaldson, Lufkin & Jenrette (now Credit Suisse), then he was Director of Finance and Strategic Planning for Fastweb from 2000 to 2004.
He has been the Chief Executive Officer of Genextra S.p.A., an investment firm focused on the life sciences industry, since July 2019 and previously served as the Chief Financial Officer from its inception in 2004. Mr. Fundarò also has served as Board Member of certain of Genextra’s portfolio companies, including Intercept Pharmaceuticals, Inc., where he has been the Chairman since October 2015 and a member of the Board of Directors since 2006, Erydel S.p.A since July 2013, Innovheart Srl since December 2015, TargImmune Therapeutics AG since September 2019.